Introduction
The continued spread of HIV, the slow progress in the development of HIV vaccines and the need for femalecontrolled technology for HIV prevention have sparked interest in the development of HIV microbicides [1] . However, clinical trials of early microbicide candidates have highlighted issues of potential mucosal toxicity, immune activation and enhanced HIV susceptibility [2] . Therefore, the identification of naturally occurring human mucosal proteins involved in protection against the sexual acquisition of HIV could be very important.
In Nairobi, Kenya, a small group of highly exposed but HIV-uninfected sex workers show no signs of infection, despite repeated exposure to HIV for as long as 20 years and are epidemiologically defined as relatively resistant to HIV infection. Immune correlates of HIV resistance include virus-specific cellular immune responses in both the systemic and mucosal compartments, as well as genital tract immunoglobulin A (IgA) with an ability to neutralize HIV and inhibit transcytosis [3, 4] . However, these adaptive immune factors alone do not fully account for the resistance phenotype.
As the initial site of HIV exposure in these women is the genital tract, we hypothesized that additional mechanisms mediating protection might be evident in genital secretions. To investigate such mechanisms, we utilized surface-enhanced laser desorption/ionization time-offlight (SELDI-TOF) mass spectrometry (MS) in an unbiased approach to screen the proteome of genital tract secretions from HIV-resistant sex workers and comparison groups. This strategy has advantages for study of mucosal material with limited sample volume in that it can quantitatively detect multiple proteins in a complex sample, can identify unknown or undescribed proteins and is a sensitive method capable of large sample throughput [5, 6] . We found that elafin/trappin-2, a small molecular weight protein, was elevated in secretions from HIV-resistant women. The association of elafin/ trappin-2 with reduced HIV susceptibility was then prospectively confirmed in an independent cohort of high-risk female sex workers (FSWs).
Materials and methods

Study populations
The initial study was performed within the well established Pumwani sex worker cohort. Three study groups (HIV-resistant, HIV-uninfected and HIV-infected women) were enrolled during ongoing biannual resurveys. Participants who had remained HIV negative for more than 3 years of follow-up by both serology and reverse transcriptase-PCR (RT-PCR), who were clinically healthy and active in sex work were defined as relatively HIV resistant [7] . HIV-uninfected sex workers were HIV-1 seronegative and active in sex work but had been followed for less than 3 years. These women come from similar socioeconomic and genetic backgrounds. In total, 321 women were enrolled in the study; however, six were later excluded from the study analysis as they met our definition of possible menopause (no menses for >4 months). As part of the resurvey, these women are routinely screened for concomitant sexually transmitted infections (STIs) (Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducrei, syphilis and bacterial vaginosis), and clinical and epidemiological information is collected by the clinic physician and study nurses. No women were found to have concomitant STIs in this study.
Prospective studies confirming the role of defined innate factors in HIV protection were performed within an independent cohort of HIV-uninfected FSWs from the nearby Kibera slum in Nairobi, Kenya. Participants had been enrolled in an immune substudy nested within a large randomized controlled trial examining the role of antibiotic prophylaxis in prevention of STI and HIV acquisition [8, 9] . This nested case-control study format has already been used to define the prospective impact of several innate and adaptive immune parameters on HIV acquisition [9, 10] . At enrollment, all Kibera FSWs underwent a complete physical examination and STI screening. Cervical swabs were collected for N. gonorrhoeae and C. trachomatis PCR (Amplicor PCR Diagnostics; Roche Diagnostic Systems, Ontario, Canada) and N. gonorrhoeae culture; Trichomonas vaginalis cultures were performed by In Pouch TV (Biomed Diagnostics, San Jose, California, USA); bacterial vaginosis was diagnosed from vaginal Gram stain based on a Nugent score of 7-10; rapid plasma reagin test (RPR test; Becton Dickinson, Groot-Bijgaarden, Belgium) was performed to diagnose syphilis, positive samples confirmed by Treponema pallidum hemagglutination assay (TPHA) (Randox Laboratories, Crumlin, UK); herpes simplex virus 2 (HSV-2) serology was performed by HSV-2 IgG enzyme immunoassay (Kalon Biological Ltd., Aldershot, UK).
All participants provided signed, informed consent, and study protocols were approved by ethics review boards at the Universities of Nairobi, Toronto and Manitoba and the Karolinska Institutet.
Sample collection
A protocol for the collection of samples and analysis by SELDI-TOF MS was developed and optimized for cervical lavage (CVL) specimens in the Pumwani cohort. Briefly, a 2 ml wash of the ectocervix was performed using sterile 1X PBS. Lavages were collected from the posterior fornix and placed in 15 ml conical tubes for transport to the laboratory on ice. Samples were aliquoted and frozen at À808C for shipment to the University of Manitoba.
Samples from participants within the Kibera cohort had been collected and cryopreserved at trial enrollment. Cervical secretion samples were obtained using a cottontipped swab, which was inserted into the cervical os and rotated 3608. A second swab was used to collect secretions from the posterior fornix, then both swabs were placed in 5 ml sterile PBS. In the laboratory, the tubes were centrifuged at 1500 revolutions/min (rpm) for 5 min to remove the cellular debris, then aliquots were frozen at À808C. IgA antibody fractions had been previously depleted for immune studies [9] ; in this study, elafin levels were determined within the IgA-depleted fraction.
Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry Assay optimization showed that the CM10 ProteinChip Array (Bio-Rad Laboratories, Mississauga, Ontario, Canada) (cation exchanger) bounds the greatest diversity of proteins from genital tract secretions and was chosen for subsequent studies. All samples were thawed on ice and equalized for freeze/thaw cycles to control for protein degradation. Protein concentrations of each sample were equalized prior to spotting onto a CM10 array. Briefly, the CM10 array was prewashed with a binding buffer (50 mmol/l sodium acetate, pH 4, 0.1% triton), and samples were loaded at a final concentration of 2 mg of protein per spot. Chips were incubated on a microplate shaker at room temperature for 1 h and then washed with a wash buffer (50 mmol/l sodium acetate, pH 4) and HPLC water. The spots were allowed to dry, and then an energy-absorbing matrix (EAM) of 50% sinapinic acid [in 0.5% trifluoroacetic acid (TFA)/50% acetonitrile] was applied. Samples were acquired on a PBS IIC SELDI-TOF MS, and univariate analysis for biomarkers was carried out using the Biomarker Wizard Software v3.1 (Ciphergen Biosystems, Fremont, California, USA).
Tandem mass spectrometry identification of protein Identification of the 6 kDa biomarker of HIV resistance was accomplished by purification from CVL samples using anion exchange chromatography (flow-through) followed by reverse phase chromatography (30% acetonitrile, 0.1% TFA). The enriched preparation was reduced, alkylated and resolved by SDS-PAGE. The gel-purified protein was reconfirmed to be the 6 kDa peak of interest by running on the SELDI-TOF MS, then digested with trypsin and unique fragments analyzed by tandem MS. Ions were fragmented by collision-induced dissociation (CID), and the MS/MS spectrum was submitted to Mascot search tool for identification (http://www.matrix-science.com/). In total, four ions from the tryptic digest of the 6 kDa protein were submitted for identification, each had extensive homology to elafin, confirming the identity of this protein.
ELISA
ELISAs were conducted using a commercial trappin-2 detection kit for the 9.9 kDa preelafin/trappin-2 form of the protein (HyCult Biotechnology, Uden, The Netherlands), as per manufacturer's instructions. An in-house ELISA was established for measurement of both the 6 kDa elafin and 9.9 kDa forms of preelafin/trappin-2 in combination. Briefly, 96-well plates were coated overnight with a polyclonal antibody specific for both the 6 and 9.9 kDa forms of elafin/preelafin (RnD Systems, Minneapolis, Minnesota, USA), blocked for 1 h with 0.17% BSA/PBS, then washed and incubated with CVL samples for 90 min at 378C. Plates were washed, and a monoclonal detection antibody specific for both the 6 and 9.9 kDa forms for elafin/preelafin was added (TRAB2F; HyCult Biotechnology), and then incubated for 90 min. Plates were then washed, and a secondary alkaline phosphatase IgG mouse antibody (SigmaAldrich, Oakville, Ontario, Canada) was added. Plates were read on an ELISA plate reader (SpectraMax 250; Molecular Devices, Sunnyvale, California, USA) at 410 nm. Finally, ELISAs for measurement of secretory leukocyte protease inhibitor (SLPI) levels were performed as per manufacturer's instructions (RnD Systems).
Statistical analysis
Statistical analysis for MS data to identify biomarkers was performed using the Ciphergen Biomarker Wizard Software v3.1 as part of the biomarker discovery platform. Confirmation of the differences between elafin/trappin-2 levels by ELISA was performed using Mann-Whitney U tests. Although a total of 579 CVL samples were assayed, some samples came from the same individual over multiple time points during the 2-year course of sample collection. The biomarker discovery data represent the aggregate mean of each individual's MS intensity for the elafin/trappin-2 peak. ELISA data are also the aggregate mean of the elafin/trappin-2 measurements per individual. It should be noted that over multiple time points, CVL levels of elafin for each individual remained relatively constant. Comparison between the MS intensity values and ELISA data for elafin/trappin-2 levels was done by Pearson's correlation test, and confounding variables were analyzed by multivariate regression analysis using SPSS (SPSS Inc., Chicago, Illinois, USA) for Windows v11.0.
The potential protective role of elafin was then tested within the independent Kibera cohort, with elafin levels assayed by investigators blind to clinical outcome. All analyses were performed with SPSS version 16.0 software. Samples with undetectable levels of innate factors were assigned a value at the assay cut-off, and levels were log 10 transformed. Sex workers acquiring HIV during clinical follow-up (cases) were matched by an external biostatistician to controls who had remained HIV uninfected, as previously described [9, 10] . Matching was based on time of study enrollment, study arm (azithromycin vs. placebo) and duration of HIVseronegative follow-up. Univariate associations of HIV acquisition were assessed in a matched case-control format, using conditional logistic regression for continuous variables. For factors associated with protection in the univariate analysis (P < 0.1), stratified multivariable analyses of the associations of HIV acquisition were performed by conditional logistic regression using a Cox proportional hazards model, with the inclusion of elafin as well as variables previously associated with HIV acquisition in the cohort. SPSS does not offer conditional logistic regression per se, and so these analyses were performed using an established adaptation of Cox regression to obtain equivalent results.
Results
Mass spectrometry identification of a biomarker of HIV resistance A total of 579 genital tract CVL samples from 321 individuals were acquired by SELDI-TOF MS (though six were excluded from subsequent analysis due to menopause). Spectral analysis revealed a number of proteins that were differentially expressed in the HIVresistant sex worker group compared with controls. The most significant of these was a 6 kDa protein overexpressed in the HIV-resistant study group compared with HIV-uninfected (P < 0.0012) and HIV-infected individuals (P < 0.0022) (Fig. 1) . This protein was subsequently purified from CVL samples and identified using tandem MS. The protein was identified as the 6.0 kDa fully processed form of trappin-2, also known as skin-derived antileukoproteinase (SKALP) or elafin.
Confirmation of elevated levels of elafin in HIV-resistant women We confirmed the elevated expression of elafin in the genital tract of HIV-resistant women, using enzyme immunoassays. As no specific antibody to the 6.0 kDa elafin protein is available and the 6 kDa elafin is a cleavage product of the 9.9 kDa trappin-2/preelafin, we were forced to quantify both the 6 and 9.9 kDa forms together, as well as measuring the 9.9 kDa fragment alone using a commercial kit. HIV-resistant individuals (mean AE SEM ¼ 0.87 AE 0.11 mg/ml) showed a two-fold increase in elafin/ trappin-2 expression compared with HIV-uninfected (mean AE SEM ¼ 0.43 AE 0.1 mg/ml) (P ¼ 0.039) and a 1.5-fold increase compared with HIV-infected (mean AE SEM ¼ 0.57 AE 0.11 mg/ml) (P ¼ 0.003) individuals (Fig. 2a) . When we determined the concentration of the 9.9 kDa form of trappin-2, the HIV-resistant individuals (mean AE SEM ¼ 0.28 AE 0.06 mg/ml) showed a 2.8-fold increase in trappin-2 levels compared with HIV-uninfected (mean AE SEM ¼ 0.1 AE 0.02 mg/ml) (P ¼ 0.008) and a 1.5-fold increase compared with HIV-infected (mean AE SEM ¼ 0.19 AE 0.03 mg/ml) (P ¼ 0.008) individuals (Fig. 2b) . The MS intensity values of the 6 kDa elafin peak positively correlated with the values obtained via the ELISA (Pearson's correlation 0.298, P ¼ 0.000001) but showed a lack of correlation with the 9.9 kDa ELISA data, illustrating the specificity of our MS approach. Interestingly, trappin-2 has significant homology with SLPI, a known inhibitor of HIV. We assessed SLPI levels in genital tract secretions by ELISA but found no differences in SLPI levels between study groups (Fig. 2c) .
Elevated elafin/trappin-2 levels were not associated with potential epidemiological confounders Many behavioral and biologic factors contribute to HIV acquisition risk (Table 1) . Analysis of epidemiological variables, such as client numbers, condom use, contraception methods, douching practices and sexual practices, showed no differences between the study groups. The HIV-resistant and HIV-infected individuals had a higher mean age when compared with the HIV-uninfected group. As expected, the HIV-uninfected sex worker Elafin associated with protection to HIV Iqbal et al. 1673 Fig. 2 . Elafin/trappin-2 is significantly overexpressed in the HIV-resistant study group as determined by ELISA. CVL samples used in the MS studies were assessed for elafin/trappin-2 levels by ELISA [HIV-uninfected (n ¼ 30), infected (n ¼ 161) and resistant (n ¼ 124) individuals]. (a) As no specific antibody exists for the 6 kDa elafin form of trappin-2, we assayed for detection of both the 6 and 9.9 kDa forms of trappin-2 by an in-house ELISA. We found an overexpression of elafin/trappin-2 in the HIV-resistant study group when compared with HIV-uninfected and HIV-infected individuals (P ¼ 0.039 and P ¼ 0.003, respectively). (b) A commercially available ELISA kit was used to quantify the 9.9 kDa form of trappin-2. Again, the 9.9 kDa form of trappin-2 was also elevated in the HIV-resistant population compared with HIV-uninfected and HIV-infected individuals (P ¼ 0.008 and P ¼ 0.008, respectively). There was no significant difference between the HIV-uninfected and HIV-infected individuals. (c) SLPI levels were assayed for in CVL samples. However, no difference was seen between HIV-resistant, HIV-uninfected and HIVinfected individuals. All bars represent the mean AE SEM; analysis was done by Mann-Whitney U test. CVL, cervical lavage; SLPI, secretory leukocyte protease inhibitor.
controls had a lower reported duration of prostitution than HIV-infected and HIV-resistant individuals. Multivariate regression analysis of elafin/trappin-2 levels showed no relationship between levels of this protein and potential confounding variables such as time from last menses, contraceptive use (reported as none, oral contraceptive, intrauterine device, depo-provera, tubal ligation, condom use or other) and douching practices (reported as daily or postcoital; washed with water, water and soap or other) (data not shown). Individuals were excluded from enrollment if they had a concomitant infection, were actively menstruating or were postmenopausal.
Prospective association of elevated elafin/ trappin-2 levels with reduced HIV acquisition Having identified and confirmed an association of elafin/ trappin-2 with HIV resistance in a cross-sectional study, we examined the association of elafin/trappin-2 with HIV acquisition within the independent Kibera sex worker cohort. Cervical secretion samples were collected at cohort enrollment, and the association of baseline elafin/trappin-2 levels with subsequent HIV acquisition was assessed in a nested, stratified case-control format. Elafin/trappin-2 levels were assayed by investigators blind to clinical outcome. Participants included 24 women who had subsequently acquired HIV (cases) and 89 matched controls who had remained uninfected. We were able to measure elafin/trappin-2 levels in 112 individuals (one sample was excluded due to inadequate CVL material). The mean elafin/trappin-2 concentration in CVL was 0.242 (SD ¼ 0.313) mg/ml, which was roughly equivalent to that found in the Pumwani cohort, despite the difference in sampling techniques (Fig. 3) . In univariate analysis, elafin/trappin-2 levels were significantly higher in persistently HIV-uninfected controls (mean AE SD ¼ 0.263 AE 0.343 mg/ml, n ¼ 89) than in those who acquired HIV (mean AE SD ¼ 0.16 AE 0.12 mg/ml, n ¼ 23; experiment B ¼ 0.35; P ¼ 0.044). There was no association of elafin/trappin-2 levels with STIs or bacterial vaginosis (0.263 mg/ml for participants with any STI or bacterial vaginosis, n ¼ 43 vs. 0.23 mg/ml for those without, n ¼ 69; P ¼ 0.62), HSV-2 infection (0.254 mg/ml for HSV-2 seropositive, n ¼ 74 vs. 0.22 mg/ml for seronegative, n ¼ 30; P ¼ 0.56) or with other potential epidemiologic confounders (data not shown).
Previous studies in this cohort have demonstrated other immune correlates of protection (genital tract HIVneutralizing IgA and systemic HIV-specific lymphocyte proliferation; [9] ), as well as behavioral associations of HIV acquisition (alcohol intake; [9] ). Multivariable models were, therefore, developed to examine the independent associations of elafin/trappin-2 with reduced HIV acquisition. The association with reduced HIV acquisition was independent of alcohol intake (P ¼ 0.015). The strength of the association remained similar with the addition of genital HIV-neutralizing IgA All numbers are mean AE SD.
M
Mean levels of age and duration of prostitution were significantly higher in the HIV-resistant and HIV-infected individuals compared with HIVuninfected individuals (P < 0.0001). Fig. 3 . Elafin/trapin-2 is elevated in women who did not seroconvert during a prospective study of HIV susceptibility. CVL samples were assessed in a sample set obtained from an independent, case-control study of HIV susceptibility. Cases are defined as the female sex workers who became HIV positive during the trial. Controls are individuals who did not acquire HIV. Elafin/trappin-2 was measured in CVL samples obtained upon enrollment and showed elevated levels in the control individuals who did not acquire HIV during the trial (P ¼ 0.044). CVL, cervical lavage.
(experiment B ¼ 0.33; P ¼ 0.07), HIV-specific proliferation (experiment B ¼ 0.21; P ¼ 0.05) or both (experiment B ¼ 0.31; P ¼ 0.19), although statistical association was lost, likely due to reduced statistical power.
Discussion
Sexual transmission of HIV is inefficient, and over 99.5% of unprotected sexual exposures do not result in production infection [11] . Therefore, even a modest enhancement in the 'bottle neck'that is presented to HIV by the mucosal barrier may have a substantial impact on transmission dynamics [12] . There are relatively few innate immune factors, which are found in the genital mucosa of men and women that have been associated with altered HIV susceptibility (reviewed in [13] ). Naturally occurring inhibitors of HIV have been found at the mucosal barrier, including SLPI and the chemokine stromal cell-derived factor 1 (SDF-1), but neither of these naturally inhibitory factors has been correlated with reduced sexual acquisition of HIV [14] [15] [16] . Although levels of the b-chemokine regulated on activation normal T-cell expressed and secreted (RANTES) may be increased in the genital tract of exposed, uninfected women [17] [18] [19] , they were also correlated with increased numbers of CD4 þ T cells in the cervical mucosa and may be induced by coinfections in high-risk women rather than mediate HIV protection [20] . Indeed, increased levels of innate factors with anti-HIV activity (a-defensins and the cathelicidin LL-37) were previously associated with coinfections and increased HIV acquisition within the Kibera cohort [10] . Therefore, prospective studies are critical to clarify the protective role of putative anti-HIV innate factors in the genital tract.
We have taken a proteomics approach to identify mucosal biomarkers of protection against HIV sexual acquisition. Recently, a two-dimensional difference gel electrophoresis (2D-DIGE) approach found elevated levels of previously described anti-HIV factors such as cystatin A in a cross-sectional study of highly exposed persistently seronegative (HEPS) women [21] . Using a different proteomics approach, we identified a novel innate factor that was elevated within the genital tract of relatively HIV-resistant FSWs. Importantly, we confirmed the association with HIV protection in an independent, prospective study of high-risk sex workers.
Trappin-2 is a member of the ALP superfamily (ALS) of protease inhibitors. The protein is produced at mucosal surfaces by epithelial cells and possibly macrophages in three major forms: a 12.3 kDa cell-associated form, as well as two secreted forms, the 9.9 kDa trappin-2/ preelafin and a 6 kDa active form known as elafin [22] . The 6 kDa elafin was the form originally identified by MS in this study; however, our ELISA data show that both elafin and the 9.9 kDa trappin-2/preelafin molecules were elevated in the CVL samples of HIV-resistant women. Trappin-2 has been largely studied in the context of lung disease, in which its antiprotease activity is thought to play a role in maintaining tissue integrity [23] . It has also been shown to have antibacterial and antiinflammatory properties [23, 24] . Interestingly, elafin/ trappin-2 also shares partial homology with SLPI, the other member of the ALS, previously shown to inhibit the infection of macrophages by HIV [15] . Despite their homology, these two proteins exhibit significant structural and functional differences [23] . Although we found elevated levels of elafin/trappin-2 in the CVL of HIVresistant women, we did not find a similar elevation in SLPI levels.
Although genital tract levels of elafin/trappin-2 were heterogeneous, elafin/trappin-2 expression was roughly two-fold higher in the HIV-resistant women. Indeed, participants with genital elafin/trappin-2 levels at least 1 SD above the nonresistant population mean were significantly less likely to be HIV infected, with a protective odds ratio (OR) of 5.9 [95% confidence interval (CI) 1.9-24.4, P < 0.006] based on the MS data and an OR of 4.5 (95% CI 1.24-24.7, P < 0.002) based on the ELISA data.
Some aspects of our findings and experimental approach merit discussion. The significantly lower age and duration of prostitution in the HIV-uninfected group in the Pumwani cohort study was expected, as these individuals tend to be new enrollees into the cohort. Despite this, regression analysis between these two variables and elafin/ trappin-2 levels showed no correlation. These variables were also controlled for during the prospective study of the Kibera cohort, and elafin/trappin-2 levels did not correlate to age or duration of prostitution. The robust nature of elafin/trappin-2 is worth noting as a biomarker for HIV resistance or protection. Despite the relatively low difference in magnitude (two-fold) between elafin/ trappin-2 levels in the HIV-resistant women and HIVuninfected women within the cross-sectional Pumwani cohort study, similar differences in genital tract elafin/ trappin-2 levels were prospectively correlated with HIV immune protection in the Kibera cohort study. An additional study to measure genetic polymorphisms or quantify elafin/trappin-2 RNA in follow-up studies may strengthen the association of this protein with protection, and perhaps address why levels may be higher in those who are resistant to infection. Finally, it is important to note that our study was limited by the selection of CM10 cationic chips to examine the CVL samples in this study. As different protein array surfaces could have captured other proteins from the lavage samples, which may have been excluded from our screening, additional biomarkers of HIV protection may be present but were not found.
Conclusion
Mucosal levels of elafin/trappin-2 were elevated in the genital tract of HIV-resistant sex workers, and the association of elafin/trappin-2 with HIV protection was confirmed in an independent, prospective study. This suggests that elafin/trappin-2 is playing an important role in mediating natural protection against HIV infection, either alone or in conjunction with other adaptive/innate protective immune mechanisms. It remains a possibility that elafin/trappin-2 may simply be a biomarker of HIV resistance or protection and may not play an active role in a mechanism of protection. Although the mechanism of action is currently not defined, the described role of elafin/trappin-2 in tissue integrity suggests that it may help to maintain an intact genital mucosal barrier. However, it will be important for future studies to also explore potential direct or indirect antiviral properties of this innate protein.
